Fierce Biotech Summit 2024

GLP-1 medications are not new; however, advancements in this class of drugs have sparked significant interest in their potential to promote weight loss, resulting in a surge of investment in obesity therapeutics. Pharma companies have made substantial commitments to this area, evidenced by the development of a robust pipeline of medications that will define the sector's trajectory for the next several decades. In this panel discussion, we’ll take an in-depth look at the topics shaping the future of obesity drugs. We’ll examine notable clinical trials, advancements in precision medicine, emerging developments in the field, and the current debate surrounding reimbursement issues.

Moderated by: Fierce Editorial Team